Karen Anobile, APRN
Psychiatric/Mental Health · Youngstown, OHNPI 1679865745
Payments from drug & device makers
Across 350 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Corium, LLC$631
- Almatica Pharma LLC$612
- Takeda Pharmaceuticals U.S.A., Inc.$412
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$379
- Supernus Pharmaceuticals, Inc.$356
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,990100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,296 |
| Corium, LLC | 37 | $631 |
| Almatica Pharma LLC | 31 | $612 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $412 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $379 |
| Supernus Pharmaceuticals, Inc. | 30 | $356 |
| Otsuka America Pharmaceutical, Inc. | 13 | $349 |
| Vanda Pharmaceuticals Inc. | 15 | $289 |
| Avanir Pharmaceuticals, Inc. | 15 | $241 |
| Lundbeck LLC | 12 | $221 |
| Axsome Therapeutics, Inc. | 7 | $190 |
| Neurocrine Biosciences, Inc. | 6 | $171 |
| Alkermes, Inc. | 9 | $168 |
| Neos Therapeutics, LP | 12 | $165 |
| Idorsia Pharmaceuticals US Inc | 3 | $119 |
| Eisai Inc. | 6 | $98 |
| Adlon Therapeutics L.p. | 3 | $40 |
| Noven Therapeutics, LLC | 2 | $38 |
| Merck | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Validus Pharmaceuticals LLC | 1 | $23 |
| Tris Pharma Inc | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Tempus AI, Inc | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Orexo US, Inc. | 1 | $13 |
How this compares
$6,003 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 42 | $71,113 |
| VraylarCariprazine Hcl | 43 | $69,896 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $40,273 |
| CaplytaLumateperone Tosylate | 13 | $31,822 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,239 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 337 | $11,571 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 61 | $10,217 |
| TrintellixVortioxetine Hydrobromide | 16 | $9,977 |
| BelsomraSuvorexant | 20 | $8,990 |
| Loreev XrLorazepam | 14 | $8,236 |
| Lisdexamfetamine Dimesylate | 28 | $7,020 |
| FetzimaLevomilnacipran Hcl | 12 | $6,870 |
| Aripiprazole | 116 | $2,768 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 63 | $2,519 |
| Trazodone Hcl | 176 | $2,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,296 | $76,76655 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $349 | $71,11342 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $241 | $40,27326 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $379 | $31,82213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $412 | $23,21652 claims |
| MerckBelsomra | $33 | $8,99020 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $612 | $8,626109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Youngstown
- Robert ParsonsYoungstown$119K
- Noah HochendonerYoungstown$34K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.